DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
Globe Newswire (Tue, 9-Jun 7:00 AM ET)
Globe Newswire (Mon, 8-Jun 4:35 PM ET)
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Globe Newswire (Fri, 5-Jun 4:30 PM ET)
Globe Newswire (Wed, 3-Jun 4:31 PM ET)
DBV Technologies Announces the Results of its 2026 Combined General Meeting
Globe Newswire (Wed, 3-Jun 4:30 PM ET)
Globe Newswire (Tue, 2-Jun 7:40 PM ET)
Combined General Meeting of June 3, 2026
Globe Newswire (Wed, 13-May 4:30 PM ET)
Globe Newswire (Tue, 12-May 4:30 PM ET)
Market Chameleon (Fri, 1-May 5:22 AM ET)
DBV Technologies Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 30-Apr 4:30 PM ET)
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
DBV Technologies S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol DBVT.
As of June 18, 2026, DBVT stock price was flat at $16.28 with 5,255 million shares trading.
DBVT has a beta of 0.08, meaning it tends to be less sensitive to market movements. DBVT has a correlation of 0.00 to the broad based SPY ETF.
DBVT has a market cap of $963.91 million. This is considered a Small Cap stock.
Last quarter DBV Technologies S.A. - American Depositary Shares reported $900,000 in Revenue and -$.11 earnings per share. This beat revenue expectation by $51,200 and exceeded earnings estimates by $.01.
In the last 3 years, DBVT traded as high as $26.19 and as low as $2.20.
The top ETF exchange traded funds that DBVT belongs to (by Net Assets): APIE.
DBVT has outperformed the market in the last year with a return of +71.9%, while the SPY ETF gained +26.3%. However, in the most recent history, DBVT shares have underperformed the stock market with its stock returning -17.9% in the last 3 month period and -8.0% for the last 2 week period, while SPY has returned +11.7% and -0.9%, respectively.
DBVT support price is $15.67 and resistance is $16.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DBVT shares will trade within this expected range on the day.